Walbert Keli reported grant involving 36,000 derivative units of Hemab Therapeutics Holdings, Inc. at $0.00 for $0 on Sep 24, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Sep 25, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
36,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
36,000Direct
Trade date
Sep 24, 2026Grant
Filed
Sep 25, 2026, 4:45 PM ET1-day reporting delay
Accession
0001193125-26-402936Code A · Transaction 229863
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

COAG price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
COAG · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 2, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: This option was granted on September 24, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from September 24, 2026 through September 24, 2029, subject to continuous service.